4-AcO-DALT

4-AcO-DALT
Clinical data
Other names	4-Acetyloxy-N,N-diallyltryptamine; 1H-Indol-4-ol, 3-(2-(di-2-propen-1-ylamino)ethyl)-, 4-acetate; 3-(2-(Di(prop-2-en-1-yl)amino)ethyl)-1H-indol-4-yl acetate; Dalcetin
Identifiers
	IUPAC name [3-[2-[bis(prop-2-enyl)amino]ethyl]-1H-indol-4-yl] acetate;
CAS Number	1445751-71-2;
PubChem CID	119025857;
ChemSpider	32078886;
UNII	2Z8WS8Z4T1;
Chemical and physical data
Formula	C18H22N2O2
Molar mass	298.386 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)Oc1cccc2c1c(c[nH]2)CCN(CC=C)CC=C;
	InChI InChI=1S/C18H22N2O2/c1-4-10-20(11-5-2)12-9-15-13-19-16-7-6-8-17(18(15)16)22-14(3)21/h4-8,13,19H,1-2,9-12H2,3H3; Key:WRHFDIBXZYYCHO-UHFFFAOYSA-N;

4-Acetyloxy-N,N-diallyltryptamine (or 4-AcO-DALT) is a tryptamine derivative. It has been sold as a designer drug, but little other information is available. It was first officially identified in seized drug samples in 2012.^[1]

References

↑ EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA (New drugs in Europe, 2012)

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA (New drugs in Europe, 2012)

[1]

See also

References